Summary:
dreaMM7: A clinical trial for patients with relapsed/refractory multiple myeloma
Multiple myeloma (MM) is a rare and currently incurable cancer. Although there have been significant advances made in treatment, many MM patients still relapse or develop treatment resistance. There is an urgent need to develop new treatments that work differently.
Why is the dreaMM7 study being done?
The dreaMM7 study is examining the effectiveness of a new combination therapy that includes a study drug called Belantamab Mafodotin (also referred to as BLENREP). The purpose of this study is to see how safe and effective belantamab mafodotin in combination with bortezomib and dexamethasone (bor/dex) is compared to daratumumab in combination with bor/dex for the treatment of relapsed/refractory multiple myeloma.
Is the dreaMM7 study an option for you?
You may be able to participate in the dreaMM7 study if:
- You are at least 18 years old
- You are diagnosed with multiple myeloma
- You have been previously treated with at least one prior line of multiple myeloma therapy
- Your cancer progressed (got worse) during or after your most recent therapy
There are other eligibility requirements that the study doctor will review with you.